UMB Bank will not increase its stake in Illumina, Inc. (NASDAQ:ILMN)

UMB Bank did not increase its stake in the shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 7.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,341 shares of the life sciences company’s stock after acquiring an additional 88 shares during the quarter. UMB Bank na’s holdings in Illumina were worth $140,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ILMN. WCM Investment Management LLC grew its position in Illumina by 2,232.3% in the first quarter. WCM Investment Management LLC now owns 3,377,221 shares of the life sciences company’s stock valued at $463,760,000 after purchasing an additional 3,232,418 shares during the last quarter. Capital World Investors purchased a new position in Illumina during the fourth quarter valued at about $271,753,000. Norges Bank purchased a new position in Illumina during the fourth quarter valued at approximately $264,636,000. Coatue Management LLC purchased a new position in Illumina during the fourth quarter valued at approximately $119,285,000. Finally, Findlay Park Partners LLP acquired a new position in Illumina in the first quarter valued at approximately $100,120,000. 89.42% of the shares are currently held by hedge funds and other institutional investors.

Analysts on Wall Street are forecasting an increase

ILMN has been the subject of several recent analyst reports. UBS Group boosted their price objective on Illumina from $131.00 to $133.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research report on Wednesday. Royal Bank of Canada restated an “outperform” rating and issued a $242.00 price objective on shares of Illumina in a research report on Wednesday, August 14th. Evercore ISI reduced their price objective on Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research report on Tuesday, June 11th. Finally, Jefferies Financial Group initiated coverage on Illumina in a research report on Monday, June 3rd. They issued a “hold” rating and a $115.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Moderate Buy” and an average target price of $151.05, according to MarketBeat.

Check out our latest report on Illumina

Illumina stock performance

NASDAQ ILMN opened at $131.40 on Friday. The stock’s fifty day moving average is $118.81, and the two hundred day moving average is $121.84. The firm has a market cap of $20.93 billion, a P/E ratio of -16.12 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36, and a current ratio of 1.75. Illumina, Inc. it has a fifty-two week low of $89.00 and a fifty-two week high of $171.50.

Illumina (NASDAQ:ILMN – Get Your Free Report ) last released its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company’s revenue for the quarter was down 5.4% compared to the same quarter last year. In the same quarter last year, the company posted earnings of $0.32 per share. On average, research analysts anticipate that Illumina, Inc. will post 1.5 earnings per share for the current year.

Illumina Company Profile

(Free report)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom and internationally. It works through Core Illumina and GRAIL segments. The company offers sequencing and array instruments and supplies, which include reagents, flow cells and library preparation; whole genome sequencing kits, which sequence whole genomes of various sizes and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured stories

Get news and reviews for Illumina Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Illumina and related companies with MarketBeat.com’s FREE daily email newsletter.